Bioseutica Research & Development teams are experts in extraction technologies, protein-purification, process engineering, and microbiological research.
We have a long track record in developing new products, proprietary production techniques and innovative applications for the food, feed, animal health and pharmaceutical industries. This is also reflected by the company's strong IP portfolio including trade-marks and patents. Bioseutica and its affiliates hold more than 15 key patents in countries all over the world as well as more than 10 new patent applications which will further strengthen the company's long-term IP position. Our IP portfolio covers a broad range of applications, and manufacturing processes in the fields of omega-3 fatty acids, Natural Proteins, and pharmaceutical applications.
Bioseutica’s team of scientists, researchers, and R&D specialists are located in Taverne (Switzerland) and Abbotsford (Canada). Bioseutica's competitive edge is due to the R&D teams' dedication to a thorough understanding of our products, our processes and of modern developments in our various fields of research. We have a track record in pioneering and leading the way in developing new market applications such as the use of lysozyme as a natural ingredient in the production of wine and beer. We have active research collaborations with world-class academic institutions and private partners such as the universities of Gent, Liegè, Edinburgh and Graz, Trinity College Dublin, Agriculture, and Agri-Food Canada. Oregon State University, Yale University, Universita di Udine, ITV France, AWRI (Australian Wine Research Institute) and the University of Wisconsin among others.
In the Natural Protein Division, the team is developing new applications for its pharmaceutical-grade lysozyme and other naturally occurring bioactive proteins. New applications are also being developed for the food protection and animal health industries. Finally, SPK-843, Bioseutica's new experimental drug for the treatment of severe, life-threatening fungal infections is currently in late-stage clinical trials.